Physician profile
Michael David
NPI 1881318699
$2,357.23
in general payments reported to CMS, 2019-2025
14 companies · $1,116 in 2025
The $1,116 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $365 · 2024: $876 · 2025: $1,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,357.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $518.40 | 2023-2025 | Jynarque |
| Ardelyx, INC. | $335.73 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Fresenius USA Marketing, INC. | $267.57 | 2024-2025 | Velphoro, Velphoro |
| Scpharmaceuticals INC. | $235.60 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.10 | 2024 | |
| Vifor Pharma, INC. | $148.89 | 2024 | Veltassa |
| Nxstage Medical, INC. | $140.60 | 2025 | Nxstage System One |
| Amgen INC. | $132.33 | 2024-2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $123.52 | 2023-2025 | |
| Travere Therapeutics, INC. | $117.90 | 2025 | |
| Calliditas Therapeutics US INC. | $100.18 | 2023 | Tarpeyo |
| Akebia Therapeutics INC | $49.14 | 2023-2024 | Auryxia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.78 | 2025 | Jardiance |
| Dexcom, INC. | $17.49 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.